An update on photodynamic therapy in age-related macular degeneration

Ehud Rechtman; Thomas A. Ciulla; Mark H. Criswell; Ayala Pollack; Alon Harris

doi:10.1517/14656566.3.7.931

An update on photodynamic therapy in age-related macular degeneration

Ehud Rechtman, Thomas A. Ciulla, Mark H. Criswell, Ayala Pollack, Alon Harris

Research output: Contribution to journal › Review article › peer-review

33 Scopus citations

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible loss of central vision in people aged > 50 years in the western world. Until recently, the only proven treatment to reduce the risk of vision loss from its more severe neovascular form was laser photocoagulation, but this treatment was suitable for only 15% of cases. Photodynamic therapy (PDT) with verteporfin was recently proposed to be effective in reducing the risk of visual loss for an estimated 20 - 30% of neovascular AMD patients. This review covers AMD epidemiology, the mechanism of PDT, the 2-year results of the two major clinical studies of PDT with verteporfin, the cost-effectiveness of PDT and the current research status of other drugs for PDT in AMD.

Original language	English
Pages (from-to)	931-938
Number of pages	8
Journal	Expert Opinion on Pharmacotherapy
Volume	3
Issue number	7
DOIs	https://doi.org/10.1517/14656566.3.7.931
State	Published - 2002
Externally published	Yes

Keywords

Age-related macular degeneration
Choroidal neovascularisation
Eye
Photodynamic therapy
Verteporfin

Access to Document

10.1517/14656566.3.7.931

Cite this

@article{cbd92fbd730f435a88aa4639439fa506,

title = "An update on photodynamic therapy in age-related macular degeneration",

abstract = "Age-related macular degeneration (AMD) is the leading cause of irreversible loss of central vision in people aged > 50 years in the western world. Until recently, the only proven treatment to reduce the risk of vision loss from its more severe neovascular form was laser photocoagulation, but this treatment was suitable for only 15% of cases. Photodynamic therapy (PDT) with verteporfin was recently proposed to be effective in reducing the risk of visual loss for an estimated 20 - 30% of neovascular AMD patients. This review covers AMD epidemiology, the mechanism of PDT, the 2-year results of the two major clinical studies of PDT with verteporfin, the cost-effectiveness of PDT and the current research status of other drugs for PDT in AMD.",

keywords = "Age-related macular degeneration, Choroidal neovascularisation, Eye, Photodynamic therapy, Verteporfin",

author = "Ehud Rechtman and Ciulla, {Thomas A.} and Criswell, {Mark H.} and Ayala Pollack and Alon Harris",

year = "2002",

doi = "10.1517/14656566.3.7.931",

language = "English",

volume = "3",

pages = "931--938",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - An update on photodynamic therapy in age-related macular degeneration

AU - Rechtman, Ehud

AU - Ciulla, Thomas A.

AU - Criswell, Mark H.

AU - Pollack, Ayala

AU - Harris, Alon

PY - 2002

Y1 - 2002

N2 - Age-related macular degeneration (AMD) is the leading cause of irreversible loss of central vision in people aged > 50 years in the western world. Until recently, the only proven treatment to reduce the risk of vision loss from its more severe neovascular form was laser photocoagulation, but this treatment was suitable for only 15% of cases. Photodynamic therapy (PDT) with verteporfin was recently proposed to be effective in reducing the risk of visual loss for an estimated 20 - 30% of neovascular AMD patients. This review covers AMD epidemiology, the mechanism of PDT, the 2-year results of the two major clinical studies of PDT with verteporfin, the cost-effectiveness of PDT and the current research status of other drugs for PDT in AMD.

AB - Age-related macular degeneration (AMD) is the leading cause of irreversible loss of central vision in people aged > 50 years in the western world. Until recently, the only proven treatment to reduce the risk of vision loss from its more severe neovascular form was laser photocoagulation, but this treatment was suitable for only 15% of cases. Photodynamic therapy (PDT) with verteporfin was recently proposed to be effective in reducing the risk of visual loss for an estimated 20 - 30% of neovascular AMD patients. This review covers AMD epidemiology, the mechanism of PDT, the 2-year results of the two major clinical studies of PDT with verteporfin, the cost-effectiveness of PDT and the current research status of other drugs for PDT in AMD.

KW - Age-related macular degeneration

KW - Choroidal neovascularisation

KW - Eye

KW - Photodynamic therapy

KW - Verteporfin

UR - http://www.scopus.com/inward/record.url?scp=0035987591&partnerID=8YFLogxK

U2 - 10.1517/14656566.3.7.931

DO - 10.1517/14656566.3.7.931

M3 - Review article

C2 - 12083992

AN - SCOPUS:0035987591

SN - 1465-6566

VL - 3

SP - 931

EP - 938

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 7

ER -

An update on photodynamic therapy in age-related macular degeneration

Abstract

Keywords

Access to Document

Fingerprint

Cite this